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Background
Methotrexate (MTX) is an efficacious drug in juvenile
idiopathic arthritis (JIA). If JIA patients are unresponsive
to MTX, effective combination treatment with biologi-
cals is required to prevent joint damage.
Aim
To develop a prediction model to identify MTX non-
responders according to the American College of Rheu-
matology 70 criteria during the first year of treatment.
Methods
Data was collected on 183 JIA patients. Clinical variables
and single nucleotide polymorphisms (SNPs) in genes
involved in the mechanism of action of MTX were
determined at baseline. Using multivariate backward
logistic regression, these variables were used to con-
struct a prediction model for MTX non-response, whose
diagnostic accuracy was evaluated. The model was sub-
sequently validated in a cohort of 104 JIA patients.
Results
The prediction model included: erythrocyte sedimenta-
tion rate and SNPs in genes coding for methionine
synthase reductase, multidrug resistance 1, multidrug
resistance protein 1 and proton-coupled folate transpor-
ter. The area under the receiver operating characteristics
curve (AUROC) was 0.73 (95%CI: 0.64-0.81). The pre-
diction model was transformed into a total risk score
(range 0 to 11). At a cut-off score of ≥3, sensitivity was
78%, specificity 49%, positive predictive value was 83%
and negative predictive value 41%. In the validation
cohort, the AUROC was 0.65 (95%CI: 0.54-0.77).
Conclusion
The prediction model we developed and validated com-
bines clinical and genetic variables to identify JIA
patients not responding to MTX treatment. This model
could assist clinicians in making individualized treat-
ment decisions.
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